Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Pharmceuticals IncfiledCriticalAmunix Pharmceuticals Inc
Priority claimed from PCT/US2020/039673external-prioritypatent/WO2020264200A1/en
Publication of MA55234A1publicationCriticalpatent/MA55234A1/en
La présente invention concerne des compositions ayant un fragment de liaison à un anticorps qui se lie spécifiquement à cd3 ou un épitope de celui-ci. Certains modes de réalisation comprennent des compositions et des fragments de liaison à des anticorps présentant une stabilité accrue. L'invention concerne également des protéines de fusion bispécifiques comprenant de tels fragments de liaison à des anticorps.The present invention relates to compositions having an antibody binding moiety that specifically binds to cd3 or an epitope thereof. Some embodiments include compositions and antibody binding fragments exhibiting increased stability. The invention also relates to bispecific fusion proteins comprising such antibody binding fragments.
MA55234A2019-06-262020-06-25
cd3 antigen binding fragments and compositions comprising them
MA55234A1
(en)